top of page

Understanding the Evolving Perspectives of Patient Advocacy Groups and Their Role in Drug Development

The Rare Advocacy Movement partnered with Covance to gain a better understanding of the evolving perspectives of patient advocacy groups (PAG's) and the various roles PAG's see themselves serving in the drug development continuum
In order to generate data to inform public discussions and to find ways to better embed the critical pulse of the patient community throughout the drug development continuum, a survey was developed, of which the insights were presented at the WODC in April of 2019 and utilized to develop the rare360 program
Preliminary Results
presented at the World Orphan Drug Congress (WODC) in Washington D.C.,
April 2019
Covance Logo_610x343.png

Covance Inc., the drug development business of LabCorp®, is the world’s most comprehensive drug development company, dedicated to advancing healthcare and delivering Solutions Made Real®. 

bottom of page